Eventide Asset Management LLC Makes New $13.33 Million Investment in Immix Biopharma, Inc. $IMMX

Eventide Asset Management LLC purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,549,019 shares of the company’s stock, valued at approximately $13,331,000.

Several other institutional investors have also added to or reduced their stakes in the business. Barclays PLC acquired a new stake in Immix Biopharma in the fourth quarter worth about $183,000. Marshall Wace LLP boosted its holdings in Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after acquiring an additional 1,923,708 shares in the last quarter. Bleichroeder LP boosted its holdings in Immix Biopharma by 17.6% in the fourth quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock worth $5,230,000 after acquiring an additional 150,000 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Immix Biopharma in the fourth quarter worth about $176,000. Finally, Jane Street Group LLC boosted its holdings in Immix Biopharma by 1,016.4% in the fourth quarter. Jane Street Group LLC now owns 167,132 shares of the company’s stock worth $874,000 after acquiring an additional 152,162 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Shares of IMMX stock opened at $8.45 on Monday. The stock has a 50 day moving average of $9.21 and a 200 day moving average of $7.62. The stock has a market cap of $459.76 million, a P/E ratio of -9.18 and a beta of 0.11. Immix Biopharma, Inc. has a twelve month low of $1.94 and a twelve month high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. On average, research analysts predict that Immix Biopharma, Inc. will post -0.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on IMMX shares. Mizuho raised their price target on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 price target on shares of Immix Biopharma in a report on Friday, March 27th. Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Tuesday, April 21st. Finally, HC Wainwright raised their price target on Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.